Kj. Mckeown et al., Altered fetal pituitary-adrenal function in the ovine fetus treated with RU486 and meloxicam, an inhibitor of prostaglandin synthase-II, BIOL REPROD, 63(6), 2000, pp. 1899-1904
Term and preterm labor are associated with increased fetal hypothalamic-pit
uitary-adrenal (HPA) activation and synthesis of prostaglandins (PGs) gener
ated through the increased expression of prostaglandin Fl synthase-ll (PGHS
-II) in the placenta. Inhibition of PGHS-II has been advocated as a means o
f producing uterine tocolysis, but the effects of such treatment on fetal e
ndocrine functions have not been thoroughly examined. Because PGE(2) is kno
wn to activate the fetal HPA axis, we hypothesized that administration of m
eloxicam, a PGHS-II inhibitor, to sheep in induced labor would suppress fet
al HPA function. Chronically catheterized pregnant ewes were treated with R
U486, a progesterone receptor antagonist, to produce active labor, and then
treated with either high-maintenance-dose meloxicam, graded-maintenance-do
se meloxicam, or a saline infusion. Maternal uterine contraction frequency
increased 24 h after the RU486 injection and the animals were in active lab
or by 48 +/- 4 h. RU486 injection led to increased concentrations of PGE(2)
, ACTH, and cortisol in the fetal circulation, and increased concentrations
of 13,14 dihydro 15-ketoprostaglandin F-2 alpha (PGFM) in the maternal cir
culation. Uterine activity was inhibited within 12 h of beginning meloxicam
infusion at both infusion regimes. During meloxicam infusion there were si
gnificant decreases in fetal plasma PGE,, ACTH, and cortisol concentrations
, and PGFM concentrations in maternal plasma. In control animals, frequency
of uterine contractions, maternal plasma PGFM, fetal plasma PGE,, ACTH, an
d cortisol concentrations increased after RU486 administration, and continu
ed to rise during saline infusion until delivery occurred. We conclude that
RU486-provoked labor in sheep is associated with activation of fetal HPA f
unction, and that this is attenuated during meloxicam treatment to a level
considered compatible with pregnancy maintenance.